← Leaderboards
Stephen J Haggarty
Massachusetts Institute Of Technology
$15,636,814
Attributed
$23,985,654
Total exposure
16
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,985,654 · 16
By mechanism
R01$20,117,238 · 8
R21$2,543,378 · 5
R33$871,652 · 1
RF1$428,922 · 1
R03$24,464 · 1
Top collaborators
- Roy H Perlis8 shared
- Jacob M. Hooker6 shared
- Joachim J Herz5 shared
- Ralph Mazitschek5 shared
- Vijaya Ramesh5 shared
- Bradford C Dickerson2 shared
- Rakesh Karmacharya2 shared
- Jen Qian Pan1 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Kevin Michael Haigis$17,260,553
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsCellsBaseResponseImageIn VitroBrainPhenotypeFunctional DisorderGene ExpressionSmall MoleculeGeneticMolecularGenesMediatingEpigenetic ProcessPathway InteractionsInduced Pluripotent Stem CellComplexAffectNeuronal PlasticityIn VivoInnovationBiochemical
Grant awards (51)
Targeting Arc to Improve Cognitive Deficits in Psychotic Disorders$825,005
R01 · FY2025 · MH
Targeting Arc to Improve Cognitive Deficits in Psychotic Disorders$826,675
R01 · FY2024 · MH
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$486,851
R01 · FY2023 · NS
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$800,931
R01 · FY2022 · NS
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$486,851
R01 · FY2022 · NS
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$800,931
R01 · FY2021 · NS
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$486,851
R01 · FY2021 · NS
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes$458,663
R01 · FY2021 · NS
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$800,931
R01 · FY2020 · NS
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$486,851
R01 · FY2020 · NS
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes$467,447
R01 · FY2020 · NS
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$800,931
R01 · FY2019 · NS
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes$567,447
R01 · FY2019 · NS
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets$503,851
R01 · FY2019 · NS
Modifiers of C9orf72 repeat dynamics$451,045
R21 · FY2019 · NS
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2019 · AT
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi$814,811
R01 · FY2018 · NS
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes$458,663
R01 · FY2018 · NS
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2018 · AT
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2018 · NS
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes$100,000
R01 · FY2018 · NS
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes$458,663
R01 · FY2017 · NS
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2017 · AT
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2017 · NS
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2016 · AT
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2016 · NS
Patient-Derived Cellular Models of Putative Antidepressants$406,970
R01 · FY2015 · AT
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2015 · NS
Autosomal Dominant FTLD Tauopathy Patient-Specific Stem Cell Models$217,500
R21 · FY2015 · NS
Functional Genomics of Neuroplasticity in Schizophrenia$605,596
R01 · FY2014 · MH · contact PI
Chemical Optoepigenetic Regulation of Chromatin-Mediated Neuroplasticity$394,763
R01 · FY2014 · NS
Autosomal Dominant FTLD Tauopathy Patient-Specific Stem Cell Models$261,000
R21 · FY2014 · NS
Functional Genomics of Neuroplasticity in Schizophrenia$596,094
R01 · FY2013 · MH · contact PI
Small-molecule probes of chromatin-mediated neuroplasticity$561,911
R01 · FY2013 · DA · contact PI
In vitro and in vivo study of simvastatin plus lithium in bipolar depression$214,664
R21 · FY2013 · MH
In vitro and in vivo study of simvastatin plus lithium in bipolar depression$191,268
R21 · FY2013 · MH
Functional Genomics of Neuroplasticity in Schizophrenia$628,625
R01 · FY2012 · MH · contact PI
Small-molecule probes of chromatin-mediated neuroplasticity$585,325
R01 · FY2012 · DA · contact PI
Genomics-Guided Characterization of iPS Cells from Common Mental Illnesses$430,823
R33 · FY2012 · MH · contact PI
Epigenomic Characterization of Alzheimer's Disease Neurons from iPSCs$428,922
RF1 · FY2012 · AG
In vitro and in vivo study of simvastatin plus lithium in bipolar depression$267,799
R21 · FY2012 · MH
Functional Genomics of Neuroplasticity in Schizophrenia$663,694
R01 · FY2011 · MH · contact PI
Small-molecule probes of chromatin-mediated neuroplasticity$597,271
R01 · FY2011 · DA · contact PI
Genomics-Guided Characterization of iPS Cells from Common Mental Illnesses$440,829
R33 · FY2011 · MH · contact PI
Small-molecule probes of chromatin-mediated neuroplasticity$615,742
R01 · FY2010 · DA · contact PI
Genomics-Guided Characterization of iPS Cells from Common Mental Illnesses$259,312
R21 · FY2010 · MH · contact PI
Small-molecule probes of chromatin-mediated neuroplasticity$621,962
R01 · FY2009 · DA · contact PI
Genomics-Guided Characterization of iPS Cells from Common Mental Illnesses$265,375
R21 · FY2009 · MH · contact PI
Discovery of potent, and selective allosteric inhibitors of GSK-3b$24,464
R03 · FY2009 · MH
Small-Molecule Probes for Conditional Modulation of the Synapse Proteome$261,515
R21 · FY2007 · MH · contact PI
Small-Molecule Probes for Conditional Modulation of the Synapse Proteome$153,900
R21 · FY2006 · MH · contact PI